Abstract
In this review we shall attempt to summarize the literature published on the high responders/low responders animal model of drug addiction. This model is based on the locomotor activity of rats in the mild stress of a novel environment. Rats that exhibit high rates of exploratory behaviours are deemed high responders (HR) and rats that exhibit low exploratory behaviours are deemed low responders (LR). Interestingly, the rate of these exploratory behaviours predicts the response of these animals to drugs of abuse. In this manuscript we will review the behavioural and physiological differences between HR and LR rats in response to d-amphemtamine, cocaine, morphine, alcohol and nicotine.
Keywords: behavioural sensitization, d-amphetamine, Conditioned Place Preference (CPP), Acute Locomotor Response, Morphine, Drug Abuse
CNS & Neurological Disorders - Drug Targets
Title: Individual Differences in Vulnerability to Drug Abuse: The High Responders/Low Responders Model
Volume: 5 Issue: 5
Author(s): Mohamed Kabbaj
Affiliation:
Keywords: behavioural sensitization, d-amphetamine, Conditioned Place Preference (CPP), Acute Locomotor Response, Morphine, Drug Abuse
Abstract: In this review we shall attempt to summarize the literature published on the high responders/low responders animal model of drug addiction. This model is based on the locomotor activity of rats in the mild stress of a novel environment. Rats that exhibit high rates of exploratory behaviours are deemed high responders (HR) and rats that exhibit low exploratory behaviours are deemed low responders (LR). Interestingly, the rate of these exploratory behaviours predicts the response of these animals to drugs of abuse. In this manuscript we will review the behavioural and physiological differences between HR and LR rats in response to d-amphemtamine, cocaine, morphine, alcohol and nicotine.
Export Options
About this article
Cite this article as:
Kabbaj Mohamed, Individual Differences in Vulnerability to Drug Abuse: The High Responders/Low Responders Model, CNS & Neurological Disorders - Drug Targets 2006; 5 (5) . https://dx.doi.org/10.2174/187152706778559318
DOI https://dx.doi.org/10.2174/187152706778559318 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Preferences of Neuroprotective S14G-Humanin Peptide Analyzed by Molecular Modeling and Circular Dichroism
Protein & Peptide Letters A Divide-and-Conquer Strategy for the Prediction of Protein Contact Map
Letters in Drug Design & Discovery Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Modulatory Effects of Food Restriction on Brain and Behavioral Effects of Abused Drugs
Current Pharmaceutical Design Precipitation of Uniform ZnO Particles with Controllable Layered Structure from Aqueous Solutions
Current Nanoscience Aerobic Exercise for Preventing Osteoporosis in Postmenopausal Women: an Update of its Effect on Bone Mineral Density
Current Rheumatology Reviews The Immunomodulating Activities of Resveratrol Glucosides in Humans
Recent Patents on Food, Nutrition & Agriculture Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets An Intelligent Three-dimensional Ultrasound Program for Rapidly Imaging of the Fetal Cranial Mid-sagittal Plane
Current Medical Imaging Midkine and Pleiotrophin in the Treatment of Neurodegenerative Diseases and Drug Addiction
Recent Patents on CNS Drug Discovery (Discontinued) Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Helper Dependent Adenovirus Vectors: Progress and Future Prospects
Current Gene Therapy